Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-19 in Relapsed/Refractory B-cell ALL
NCT02810223Phase 1Unknown
- Sponsor
- Beijing Sanwater Biological Technology Co., Ltd.
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19 CAR-T cells in acute lymphoblastic leukemia (ALL), sponsored by Beijing Sanwater Biological Technology Co., Ltd. Primary endpoint: Number of Adverse Events at 2 years. Status: unknown.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02810223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02810223.